US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
To-be Listed (Grey Market Trading Session: 16:15-18:30)
Name
/
Code
Industry Listing Price Lot Size Entry Fee Phillip Grey Market Futu (HK) Grey Market
REFIRE
02570.HK
Grey Market Today
Electrical Components & Equipment Pending 20 3,333
-
-
Detail Quote
Dmall
02586.HK
Grey Market Today
Application Software 30.210 100 N/A
-
-
Detail Quote
Last update: 2024-12-05 08:30:05
Name
/
Code
Industry Offer Price Lot Size Entry Fee Closing Date
Grey Market Date
Listing Date
Mao Geping
01318.HK
Beauty & Toiletries Products and Services 26.3-29.8 100 3,010 2024/12/05 2024/12/09 2024/12/10
Summary
Founded in 2015, we are a clinical-stage biotech company exclusively focused on biologic therapies for autoimmune and allergic diseases. We have two Core Products, QX002N and QX005N, both of which are self-developed. QX002N is an IL-17A inhibitor and we have initiated a Phase III clinical trial for ankylosing spondylitis (AS) in China. QX005N is a monoclonal antibody (mAb) blocking IL-4R and we have initiated Phase II clinical trials for atopic dermatitis (AD), prurigo nodularis (PN) and chronic rhinosinusitis with nasal polyps (CRSwNP) in China. As of the Latest Practicable Date, we had seven other pipeline drug candidates in addition to our Core Products, four of which were in the clinical stage. Our pipeline covers four major areas in the autoimmune and allergic disease field, namely, skin, rheumatic, respiratory and digestive diseases.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET OUR CORE PRODUCTS AND OTHER PIPELINE PRODUCTS SUCCESSFULLY.

Our Core Products

QX002N

One of our Core Products, QX002N, is a high-affinity monoclonal antibody (mAb) targeting IL-17A, a key player in the pathological mechanism of various autoimmune diseases. IL-17A inhibitors are recommended by prevailing clinical guidelines as second-line standalone treatment (the same designation as TNF inhibitors) for AS patients with high disease activity after receiving first-line traditional treatments. Between the two classes of biologics (i.e., TNF inhibitors and IL-17A inhibitors), IL-17A inhibitors have shown clear clinical benefit in patients who are intolerant to or fail to achieve adequate disease control with TNF- inhibitors.

We have obtained IND approval for QX002N for AS and LN and plan to prioritize the development of the former indication. QX002N demonstrated promising efficacy in our Phase Ib and Phase II clinical trials for AS. In our Phase Ib clinical trial, 62.5% and 37.5% of subjects receiving QX002N (160 mg) once every 2 weeks achieved Assessment of Spondyloarthritis International Society 20 (ASAS20, defined as 20% improvement from baseline in the ASAS score) and ASAS40 (defined as 40% improvement from baseline in the ASAS score) responses at week 16, respectively. In our Phase II clinical trial, the ASAS20 and ASAS40 response rates of subjects receiving QX002N (160 mg) once every 4 weeks reached 60.0% and 40.0% at week 16, respectively. ASAS20 and ASAS40 indicate 20% and 40% improvement, respectively, from baseline in the ASAS score, a widely used measurement of symptom improvement for AS patients. We conducted a pre-Phase III consultation with the NMPA, which raised no material questions and confirmed that it had no objections to the commencement of such trial in its official response in July 2023. We commenced the Phase III clinical trial in September 2023 and expect to complete it in the second half of 2025.

Addressable Market and Competitive Landscape

According to Frost & Sullivan, the prevalence of AS in China was 3.9 million in 2022, and is estimated to reach 4.0 million in 2030. The AS drug market in China was US$1.8 billion in 2022, and is estimated to reach US$6.5 billion in 2030, at a CAGR of 17.4%. Upon its approval and commercialization, we expect QX002N to face intense competition from approved biologic drugs from multinational pharmaceutical companies as well as potential competition from drug candidates in clinical development in China for AS. As of the Latest Practicable Date, such drugs and drug candidates were exclusively TNF inhibitors and IL-17 inhibitors. The TNF inhibitors include adalimumab and numerous adalimumab biosimilars and proposed biosimilars. As of the Latest Practicable Date, there were two IL-17A antibody drugs approved for AS treatment in China, namely, secukinumab and ixekizumab, both of which had also been approved by the FDA. As of the same date, in addition to our QX002N, there were ten IL-17-targeting biologic drug candidates indicated for AS in the clinical stage in China. The following table sets forth details of QX002N and IL-17 antibody drugs or drug candidates for AS in the clinical stage in China as of the Latest Practicable Date.

QX005N

Our other Core Product, QX005N, is designed to inhibit IL-4R, a validated target investigated for a wide range of indications. Because IL-4R controls the signaling of both IL-4 and IL-13, which is critical in the initiation of type 2 inflammation (an overactive immune response driven by certain type 2 immune cells), it has emerged as a key target for new drug development in related indications. According to Frost & Sullivan, IL-4R inhibitors had been approved or were under development for 20 indications globally as of the Latest Practicable Date. Dupilumab, the first FDA-approved IL-4R inhibitor, is one of the best-selling biologic drugs globally for allergic diseases, with annual sales of US$8.7 billion in 2022.

As of the Latest Practicable Date, we had obtained seven IND approvals for QX005N (namely, AD in adults, AD in adolescents, PN, CRSwNP, CSU, asthma and COPD). QX005N demonstrated favorable safety and efficacy results in our Phase Ia and Phase Ib clinical trials for AD. In the Phase Ib clinical trial in patients with moderate-to-severe AD, in each of the 300 mg and 600 mg groups, 75.0% of subjects achieved Eczema Area and Severity Index-75 (EASI-75) responses (defined as 75% improvement from baseline in the EASI score) and 50.0% of subjects reached Investigator’s Global Assessment (IGA) scores (0 or 1) at week 12 without significantly increased safety risks. We have started a Phase II clinical trial for AD and completed patient enrollment in February 2023. In September 2023, we conducted a formal consultation with the CDE of the NMPA inquiring whether the NMPA had any objections to or additional requirements on our conduct of the Phase Ib/Phase II clinical trial, and the NMPA did not raise any objections or additional requirements. In addition, we commenced a Phase II clinical trial for PN in February 2023. According to Frost & Sullivan, QX005N was the first biologic drug candidate developed by a Chinese domestic company to start a clinical trial for PN in China. In January 2024, the CDE granted QX005N the breakthrough therapy designation for the treatment of PN, signifying its superior clinical benefits compared to current treatment methods. The designation is designed to expedite the development and regulatory review of innovative drugs demonstrating substantial potential in addressing serious conditions. We also commenced a Phase II clinical trial of QX005N for CRSwNP in April 2023.

Addressable Market and Competitive Landscape

Upon approval and commercialization of QX005N, we expect it to face intense competition from approved biologic drug as well as potential competition from drug candidates in clinical development in China for the same indication. The industry landscapes of the major indications in China are as follows:

‧ AD. According to Frost & Sullivan, the prevalence of AD in China was 70.3 million in 2022, and is expected to reach 78.5 million in 2030. The AD drug market in China was US$1.0 billion in 2022, and is estimated to grow rapidly to reach US$7.1 billion in 2030, at a CAGR of 23.3%. As of the Latest Practicable Date, dupilumab was the only biologic drug approved in China for AD, which had also been admitted to the NRDL. As of the same date, there were 21 biologic drug candidates for AD in the clinical stage in China, among which 10 were IL-4R inhibitors. Biologics targeting IL-13, TSLP, IL-33, ST2, CD200R, OX40, IL-2R and IL-17RB are also being developed for AD. The following table sets forth details of QX005N as well as approved biologic drugs and drug candidates for AD in the clinical stage in China that target IL-4R as of the Latest Practicable Date.

‧ PN. According to Frost & Sullivan, the prevalence of PN in China was 2.0 million in 2022, and is estimated to reach 2.1 million in 2030. Development of the PN drug market in China is still at an early stage with dupilumab being the only biologic drug approved in China as of the Latest Practicable Date. As of the same date, there were only two biologic drug candidates for PN in the clinical stage in China, both of which were IL-4R inhibitors, as set out below.

‧ CRSwNP. According to Frost & Sullivan, the prevalence of CRSwNP in China was 20.4 million in 2022, and is estimated to reach 22.3 million in 2030. The CRSwNP drug market in China was US$141.7 million in 2022, and is expected to reach US$633.4 million in 2030, at a CAGR of 20.6%. As of the Latest Practicable Date, no biologic drug had been approved for the treatment of CRSwNP in China. As of the same date, there were 13 biologic drug candidates for CRSwNP in the clinical stage in China, including six IL-4R inhibitors. Biologics targeting IL-5 and TSLP are also being developed for CRSwNP. The following table sets forth details of QX005N as well as the biologic drug candidates for CRSwNP in the clinical stage in China as of the Latest Practicable Date.

Our Other Key Drug Candidates

‧ QX001S: QX001S is our first expected commercial drug, the first domestically developed ustekinumab biosimilar with BLA submitted in China and potentially one of the first ustekinumab biosimilars to be approved in China, which targets IL-12/IL-23p40 and has been widely regarded as one of the major treatments for Ps worldwide. In our Phase I clinical trial for Ps, QX001S demonstrated a safety and PK profile comparable to that of ustekinumab. In our Phase III clinical trial for Ps, QX001S demonstrated clinical equivalence to ustekinumab in terms of efficacy, safety, immunogenicity and PK profile. Zhongmei Huadong, a subsidiary of Huadong Medicine and our commercialization partner for QX001S, submitted a BLA in China in July 2023, which was accepted by the NMPA in August 2023 and under review as of the Latest Practicable Date. We expect QX001S to face fierce competition upon its commercialization, especially considering that the other two ustekinumab biosimilar candidates in China commenced their Phase III clinical trials at a similar time as our Phase III trial. See “Risk Factors—Our drug candidates will be subject to intense competition with biologics drugs and other drugs for autoimmune and allergic diseases after commercialization and may fail to compete effectively against competitors” for details.

‧ QX004N: We are developing QX004N, an IL-23p19 inhibitor, for Ps and CD. We completed a Phase Ia clinical trial of QX004N in healthy subjects for the Ps indication in China in September 2023 and QX004N showed a good safety profile. As of September 30, 2023, we had also commenced a Phase Ib clinical trial and a Phase II clinical trial in China to evaluate QX004N for this indication and expect to complete them in the second quarter of 2024 and the first half of 2025, respectively. We also commenced a Phase Ia clinical trial for CD in China in February 2023.

‧ QX006N: We are developing QX006N, an IFNAR1-targeting mAb, for the treatment of SLE, a difficult indication for new drug development. The first-in-class IFNAR1 inhibitor, SAPHNELO (anifrolumab), was approved by the FDA in 2021, making it the only new SLE treatment in more than 10 years. As of the Latest Practicable Date, our QX006N was one of the only two IFNAR1 inhibitors developed by Chinese domestic companies that had entered the clinical stage for SLE in China. QX006N showed a good safety profile in our Phase Ia clinical trial, and promising potency and affinity comparable to those of an internally prepared anifrolumab analog in our preclinical studies. We initiated a Phase Ib clinical trial in SLE patients in March 2023 and expect to complete such trial in the fourth quarter of 2024.

‧ QX008N: QX008N is a humanized IgG1 mAb targeting TSLP, designed for the treatment of moderate-to-severe asthma and moderate-to-severe COPD. TSLP-targeting therapy is the only class of biologic drugs globally approved for asthma that can slow disease progression for asthma patients with low-level or no expression of type 2 biomarkers. QX008N demonstrated a potency superior to an internally prepared tezepelumab analog and exhibited a good safety profile in our Phase Ia clinical trial. We commenced a Phase Ib clinical trial in adult patients with moderate-to-severe asthma in August 2023, the remainder of which will be completed by Joincare, our licensing partner.



Source: Qyuns Therapeutics-B (02509) Prospectus (IPO Date : 2024/03/12)
Listing Market MAIN
Industry Biotechnology - Pharmaceuticals
Background H Shares
Major Business Area N/A
Corporate Information
Substantial Shareholders Qiu Jiwan & Associates (Total share: 31.77%); (H share: 29.57%)
Huadong Medicine Co., Ltd. (Total share: 17.06%); (H share: 18.50%)
Taizhou Medicine City Holding Group Co., Ltd. (Total share: 16.18%); (H share: 17.55%)
Taizhou Xinfu Tongxin Enterprise Management Partnership (Limited Partnership) (Total share: 7.00%); (H share: 7.59%)
Matrix China Management VI, L.P. (Total share: 4.92%); (H share: 5.33%)
Directors Qiu Jiwan (Chairman and General Manager and Chief Executive Officer and Executive Director)
Lin Weidong (Deputy General Manager and Executive Director)
Wu Yiliang (Executive Director)
Wu Zhiqiang (Non-Executive Director)
Xue Mingyu (Non-Executive Director)
Yu Xi (Non-Executive Director)
Fung Che Wai, Anthony (Independent Non-Executive Director)
Ling Jianqun (Independent Non-Executive Director)
Zou Zhongmei (Independent Non-Executive Director)
Company Secretary Hu Yanbao
Tang King Yin
Principal Bankers China Merchants Bank
Shanghai Pudong Development Bank Co., Ltd.
Solicitors JunHe LLP
Sidley Austin
Auditors KPMG
Registered Office 5th Floor, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong
Share Registrars Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No (852) 2980-1333
Internet Address http://www.qyuns.net
Email Address [email protected]
Tel No (86 523) 8027-6311
Fax No
 
SITEMAP
Email: [email protected]
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
Disclaimer
You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.